DOCSLIB.ORG

Patent Application Publication Oo) Pub. No.: US 2012/0301400 Al Williams Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patent Application Publication Oo) Pub. No.: US 2012/0301400 Al Williams Et Al US 20120301400A1 US 20120301400A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2012/0301400 Al Williams et al. (43) Pub. Date: Nov. 29,2012 (54) MEDITOPES AND MEDITOPE-BINDING (30) Foreign Application Priority Data ANTIBODIES AND USES THEREOF Oct. 10, 2011 (US) ................. PCT/US2011/055656 (76) Inventors: John C. Williams, Monrovia, CA (US); David A. Horne, Duarte, CA Publication Classification (US); Yuelong Ma, Duarte, CA (51) Int. Cl. (US); Heng Wei Chang, Foster C07K16/18 (2006.01) City, CA (US); Joshua Michael C07K 7/08 (2006.01) Donaldson, Lumberton, NJ (US); C07K1/14 (2006.01) Cindy Zer, Duarte, CA (US); A61K 39/395 (2006.01) Krzysztof Bzymek, Pasadena, CA A61K 49/00 (2006.01) (US); Kendra Nicole Avery, C12N 5/071 (2010.01) Pasadena, CA (US); Jun Xie, C07K 7/06 (2006.01) Duarte, CA (US) C07K2/00 (2006.01) (21) Appl. No.: 13/443,804 (52) U.S. Cl......... 424/9.1; 530/387.9; 530/330; 530/329; 530/328; 530/327; 530/326; 530/321; 424/139.1; (22) Filed: Apr. 10, 2012 424/178.1; 435/331 Related U.S. Application Data (57) ABSTRACT (63) Continuation-in-part of application No. 13/270,207, Antibodies and meditopes that bind to the antibodies are filed on Oct. 10, 2011. provided, as well as complexes, compositions and combina­ (60) Provisional application No. 61/391,558, filed on Oct. tions containing the meditopes and antibodies, and methods 8, 2010, provisional application No. 61/597,708, filed of producing, using, testing, and screening the same, includ­ on Feb. 10, 2012. ing therapeutic and diagnostic methods and uses. Patent Application Publication Nov. 29, 2012 Sheet I of 79 US 2012/0301400 Al figure I Al v* Vt V fed! tope €h *·'·> ·■ . !*0 C ' Λίί ? 1O > ■? ' (S Q1 i " PatentApplicationPublication Nov. 29,2012 Sheet 2 of 79 US 2012/0301400 Al ISprei m Light Chain Kat>as Muonic 10 3S->_4S SS--I? iso—iss m I cmlps pffrr MStmM I I cpffcp 1c:#yf e I £}IC|1K« Ρ|ΥΥ I? Hmty Cltaln KaSst IKaaitef 33,,,,,.,,,44 BMm imsm m nsan CEMmimaM QStMM? TMi S PA .............■ ■ ■ ■ yP ^aaa SMi S PA trastua ama b QSSSKS TM E ES Patent Application Publication Nov. 29, 2012 Sheet 3 of 79 US 2012/0301400 Al Pigwt 3 Patent Application Publication Nov. 29, 2012 Sheet 4 of 79 US 2012/0301400 Al Fig»** 4 A-C Λ(·ΐϊ::ίί?ί· jsMA il-rj-R. -V i '·, C&w&mte J VAFsb I /I -;v Fafo .,.Domalrs Ifo ··: .·.·····:·:·. j· m n- F/adtepe FSTC Patent Application Publication Nov. 29, 2012 Sheet 5 of 79 US 2012/0301400 Al 0 0 211 48 m 80 100 fpll) wf:¥ Ii 2,0 Patent Application Publication Nov. 29, 2012 Sheet 6 of 79 US 2012/0301400 Al FigareS i;.-· 1® I Patent Application Publication Nov. 29, 2012 Sheet 7 of 79 US 2012/0301400 Al Fifttre $ ..... ' ' J >ϊ Ϊ JlliS i Mednope Meditopo w-Modi Iepe w Aleditope w?· Af\) j !Hill Patent Application Publication Nov. 29, 2012 Sheet 8 of 79 US 2012/0301400 Al figure 7 PfDlein A Patent Application Publication Nov. 29, 2012 Sheet 9 of 79 US 2012/0301400 Al Figure 8 Cetuximab TOPVIEW Matuzumab/425 Tumor Cell Multivalent Meditope Tumor Antigen Antibody "Daisy Chained" TOPVIEW Patent Application Publication Nov. 29, 2012 Sheet 10 of 79 US 2012/0301400 Al Wi fare 9 Fab variable light chain variable heavy chain Linkers PatentApplication Publication Nov. 29, 2012 Sheet 11 of 79 US 2012/0301400 Al FigtiM 1® PatentApplication Publication Nov. 29, 2012 Sheet 12 of 79 US 2012/0301400 Al Ftgmelt Tumor Association Protease Site Patent Application Publication Nov. 29, 2012 Sheet 13 of 79 US 2012/0301400 Al Figure 12 Momvglmt Modftopn TetmvMont Modiiopo ··;*· O- p β .,,,,;¾.- Oi* O .#·Λ Time iem tims md PatentApplication Publication Nov. 29, 2012 Sheet 14 of 79 US 2012/0301400 Al PigarK LI Ά KiCO3, H2N,. MO^JvOH 'NH3 3-bmrm>4fofftpyne I! J DMF ®C«Wft8 CDOMe COOMe 4 N » H tof ifimens linker € E! * H tar riknerie linker SRsOH for irimsrift lirskef ? R‘« Q''""''%,lef Himerift Sinfcer **■·.,V"··, ,ο,. YΛ'" Ον-·"·-..^·„0# FiTO DiEH iVti DMF I H H i Ff * H for sSmesks Iinfcer ISRi-HfofdsmeriRlfoksr S R' ~ irinsene SirHer 11 RF* t©f Himsrift inker Mj r~f,ft t i ^ Αν,χννΧ·.,#ί (PfO)ij I '" ISeriI C&SO4-fsssorbaie (I-Qfdlstrrlho O-QFOLSTRRLkvO ----------------------------------------* DiEA. DMF S-----------------------1 H2Oi ecetmttrlfo 2 QvmV^ θΐ§·: I H A tV >s%x<Ff 0¼ (EfO)D-Nfo*N R* 0¾¾! I O-QFOLSTR RLKvO om,RRTSLOFQ-Q i_____________ I 14 Fr » H, dimeric fSeemsceirs iabsfori Sadam «■ 'Xfo--Xx 14 Fr « s-ftLRgrsusfto-s- trimerfc ifoereseein Hfteieri lsefom Patent Application Publication Nov. 29, 2012 Sheet 15 of 79 US 2012/0301400 Al fiftire M m m m e »»»»»»»»»»»>»»»»»»»»»»»·_·: 1θ IS »3« :?-3 ;:i i I *1 I sI .T I I I 4Cii --::::.3 "I 3013343 I 3-2 2I wmjtm 33-0 /::4 3; ^■V! 3 543? 3000 3/332?? $4 < ΐ44 :2 s 3 - 4 . '3 .. .. .λ .w-:-4:-.;·:· ■■·;·;■ SCiS 300 iOOO OOO i 400 Patent Application Publication Nov. 29, 2012 Sheet 16 of 79 US 2012/0301400 Al ftgttre 14 L I «■""it ¥·® m ................. I !fill Il %|" I....................................ί i«·χ·χ·χ·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·: IbrZ * δ Expected MW: 858.8328 Found MW: 858.8294 PatentApplication Publication Nov. 29, 2012 Sheet 17 of 79 US 2012/0301400 Al Figure IS MedfcopeMFc (SEQ UD NOD miciefc acid aod SEQ ID NO; 4 αΜαά add) R; ex;; ;: a qR: R i: a a < x: R: <; I: ·;:: * a <; R: a:; a <: q a;; R .q: s a a i; ¢ :; a qqi: C 0' F "a R-" S F p' RR F K C F qAAAqaF AaqqR Re A.aqaR: AAqqaqqReqR aqqqqqcxxERaaF AFRAqqaaaqR.qqa Ra q S GFFFFF F F F FFFF F F F F F F :: q qq.:;R a. a q ; · c c:;:aq qq c q ·: q R qAR as q F < s a a::; q q aa a q q < a;c :;q <: F ;: i χ :a:. q a a a:q a: F a;s. F "a k" I'" F F FFFF F 'a F "f" f' F "f ' rr" F F q F aa; Raq a aqqa:: qqqq aaacqaa Fiaaqq aa a R.qq a aar FFaaaaiqq aaa aaaa aqa q 'v F F F F F K F a 'a F R,' Vi:" I F F x" f'"f 'p aaasF FF FFqqF Aqqqq a a.Ftqq aaaaFFF FqaFc aqqqqqF aaaaFF aaaRF aa a AaaF f I C F V F D F F F F D FEVK F FWFV a a a a q a q a aaa ¢:; fit aaa aaa a a a q q q q aaa a; q -a aa aa a aaaa q aa aa; a a F aa a a t F a a aa a D G F E V F W a K T K F F E F a a r;; a T ;; FFaaaatqaaataqqFaataiqsaiFK; agt; CKaaFq aaaaq';a:iaa;:.qqa IaaiFaaaaaaqaq:; F R V V F V L T F L F 0 a q a q; a r; E V a a aa q a a a a aa a aa aa a aa a a a a a at aaa; F a a a a aa a a a aa a aa. aa a aa Ra a a q aa. a aa q K C R F F F k ’ f. ’ I,' a F F F £ K X F S K ’ ’ F ’ a a aa a a a; a a aa a Aq aaa aa; aa; a a a aa: a Fa. aa a aaa R; F a; cq a;a; a a: a aaa a a a a; t aa a a ct. a; af; a K a F a- R F F Fi F V X L f" p F p'g p' e X a a aa a; a a a a AR a Ff cat; aa. a R a at; R R a FR aaa a a RRA R R a R a a aa q R a aaa a a F a rr a a FR a K W 0' V F R T F X:' "v K G P X p' a"P X A "v a a at rk:; q a RR Re a aa R aa a a a a a a-q qa a aa aa cr a R a a a a a aa a aa a a a q aaa a R a R R a aa a X F X a’ FR "p' 0 p' "a RR Ri P K T X p' F F R.· F R -CaxRARiRaiaRaaRAaiaR R eR.a R AR: Rq;a AR; RKFRqaiARxP:,aaa A RRAXiRxiAA qqR: AAiRAqqaA' F "a "0 Rr" P F I: X p' K" F X "a "a k' Rr" p' w" o' 0' q ARAqqq:: a Ra iaRccKcqcR AAiRRqqR ckraRx; AqaaaqR R aaa aa R aacR: a R A.aqca aaaa RC K V P a F a F RR RR R A G Ri W K X F Q K aqaqR AAqq At CRR.aqqciKqqqq a a kra A .R: a F a Ri a Patent Application Publication Nov. 29, 2012 Sheet 18 of 79 US 2012/0301400 Al I1psr« M PatentApplication Publication Nov. 29, 2012 Sheet 19 of 79 US 2012/0301400 Al Flgere 17 iSif-'-f'" "V. 3 I Meditope-Fc ·:·:·/ - SJ j K 1 SJ Meditope monomer sV kuX V QA ί»5 W Patent Application Publication Nov.
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials
    Wu et al. Cancer Drug Resist 2018;1:204-18 Cancer DOI: 10.20517/cdr.2018.16 Drug Resistance Review Open Access Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials Xiaorong Wu, Thomas Kilpatrick, Ian Chau Department of Medical oncology, Royal Marsden Hospital NHS foundation trust, Sutton SM2 5PT, UK. Correspondence to: Dr. Ian Chau, Department of Medical Oncology, Royal Marsden Hospital NHS foundation trust, Downs Road, Sutton SM2 5PT, UK. E-mail: [email protected] How to cite this article: Wu X, Kilpatrick T, Chau I. Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials. Cancer Drug Resist 2018;1:204-18. http://dx.doi.org/10.20517/cdr.2018.16 Received: 31 Aug 2018 First Decision: 8 Oct 2018 Revised: 13 Nov 2018 Accepted: 16 Nov 2018 Published: 19 Dec 2018 Science Editors: Elisa Giovannetti, Jose A. Rodriguez Copy Editor: Cui Yu Production Editor: Huan-Liang Wu Abstract Gastrointestinal (GI) cancers represent the leading cause of cancer-related mortality worldwide. Antibody drug conjugates (ADCs) are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival. ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy. Currently, only two ADCs [brentuximab vedotin and trastuzumab emtansine (T-DM1)] have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer, respectively. Clinical research evaluating ADCs in GI cancers has shown limited success. In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets.
    [Show full text]
  • Immunotherapy in Various Cancers
    © 2021 JETIR June 2021, Volume 8, Issue 6 www.jetir.org (ISSN-2349-5162) Immunotherapy in various Cancers Nirav Parmar 1st Year MSc Student Department of Biosciences and Bioengineering, IIT- Roorkee India Abstract: Immunotherapy in the metastatic situation has changed the therapeutic landscape for a variety of cancers, including colorectal cancer. Immunotherapy has firmly established itself as a new pillar of cancer treatment in a variety of cancer types, from the metastatic stage to adjuvant and neoadjuvant settings. Immune checkpoint inhibitors have risen to prominence as a treatment option based on a better knowledge of the development of the tumour microenvironment immune cell-cancer cell regulation over time. Immunotherapy has lately appeared as the most potential field of cancer research by increasing effectiveness and reducing side effects, with FDA-approved therapies for more than 10 various tumours and thousands of new clinical studies. Key Words: Immunotherapy, metastasis, immune checkpoint. Introduction: In the late 1800s, William B. Coley, now generally regarded as the founder of immunotherapy, tried to harness the ability of immune system to cure cancer for the first time. Coley began injecting live and attenuated bacteria like Streptococcus pyogenes and Serratia marcescens into over a thousand patients in 1891 in the hopes of causing sepsis and significant immunological and antitumor responses. His bacterium mixture became known as "Coley's toxin" and is the first recorded active cancer immunotherapy treatment [1]. To better understand the processes of new and traditional immunological targets, the relationship between the immune system and tumour cells should be examined. Tumours have developed ways to evade immunological responses.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
    US009 161992B2 (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies et al. (45) Date of Patent: Oct. 20, 2015 (54) P97 FRAGMENTS WITH TRANSFER 4,683.202 A 7, 1987 Mullis ACTIVITY 4,704,362 A 11/1987 Itakura et al. 4,766,075 A 8, 1988 Goeddeletal. (71) Applicant: biosis Technologies, Inc., Richmond 4,800,1594,784.950 A 11/19881/1989 MullisHagen et al. (CA) 4,801,542 A 1/1989 Murray et al. 4.866,042 A 9, 1989 Neuwelt (72) Inventors: Wilfred Jefferies, South Surrey (CA); 4,935,349 A 6/1990 McKnight et al. Mei Mei Tian, Coquitlam (CA): 4.946,778 A 8, 1990 Ladner et al. Timothy Vitalis, Vancouver (CA) 5,091,513 A 2f1992 Huston et al. 5,132,405 A 7, 1992 Huston et al. (73) Assignee: biOasis Technologies, Inc., British 5, 186,941 A 2f1993 Callahan et al. Columbia (CA) 5,672,683 A 9, 1997 Friden et al. 5,677,171 A 10, 1997 Hudziak et al. c - r 5,720,937 A 2f1998 Hudziak et al. (*) Notice: Subject to any disclaimer, the term of this 5,720,954. A 2f1998 Hudziak et al. patent is extended or adjusted under 35 5,725,856 A 3, 1998 Hudziak et al. U.S.C. 154(b) by 0 days. 5,770,195 A 6/1998 Hudziak et al. 5,772,997 A 6/1998 Hudziak et al. (21) Appl. No.: 14/226,506 5,844,093 A 12/1998 Kettleborough et al. 5,962,012 A 10, 1999 Lin et al.
    [Show full text]
  • Veltuzumab, an Anti-CD20 Mab for the Treatment of Non-Hodgkin's
    Current Opinion in Molecular Therapeutics 2009 11(2):200-207 Thomson Reuters (Scientific) Ltd ISSN 2040-3445 DRUG PROFILE Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura Cannon Milani & Jorge Castillo* Address Brown University Warren Alpert Medical School, The Miriam Hospital, Division of Hematology and Oncology, 164 Summit Ave, Fain Building, Providence, RI 02906, USA Email: [email protected] *To whom correspondence should be addressed Veltuzumab is a humanized, second-generation anti-CD20 mAb currently under development by Immunomedics Inc for the potential treatment of B-cell non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Licensee Nycomed is developing veltuzumab for the potential treatment of rheumatoid arthritis and immune thrombocytopenic purpura (ITP). Veltuzumab contains 90 to 95% human antibody sequences with identical antigen framework regions to epratuzumab (a humanized anti-CD22 mAb) and similar antigen-binding determinants to rituximab (chimeric, anti-CD20 mAb and the first-line treatment of aggressive and indolent NHL). In vitro studies have demonstrated that veltuzumab has enhanced binding avidities and a stronger effect on complement-dependent cytotoxicity compared with rituximab in selected cell lines. In dose-finding phase I/II clinical trials in patients with low-grade NHL, intravenous veltuzumab demonstrated a substantial rate of complete responses in concurrence with shorter and more tolerable infusions compared with rituximab. Currently there has been no evidence of an immune response to repeated administrations, and no serious adverse events related to veltuzumab treatment in patients with NHL. Veltuzumab is undergoing clinical trials using a low-dose subcutaneous formulation in patients with NHL, CLL and ITP.
    [Show full text]
  • TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (Egfrt)
    (19) TZZ _T (11) EP 2 496 698 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 14/71 (2006.01) C12N 9/12 (2006.01) 09.01.2019 Bulletin 2019/02 (86) International application number: (21) Application number: 10829041.2 PCT/US2010/055329 (22) Date of filing: 03.11.2010 (87) International publication number: WO 2011/056894 (12.05.2011 Gazette 2011/19) (54) TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION VERKÜRZTER REZEPTOR FÜR DEN EPIDERMALEN WACHSTUMSFAKTOR-REZEPTOR ZUR AUSWAHL UMGEWANDELTER T-ZELLEN RÉCEPTEUR DU FACTEUR DE CROISSANCE DE L’ÉPIDERME TRONQUÉ (EGFRT) POUR LA SÉLECTION DE LYMPHOCYTES T TRANSDUITS (84) Designated Contracting States: • LI ET AL.: ’Structural basis for inhibition of the AL AT BE BG CH CY CZ DE DK EE ES FI FR GB epidermal growth factor receptor by cetuximab.’ GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO CANCER CELL vol. 7, 2005, pages 301 - 311, PL PT RO RS SE SI SK SM TR XP002508255 • CHAKRAVERTY ET AL.: ’An inflammatory (30) Priority: 03.11.2009 US 257567 P checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral (43) Date of publication of application: tissues.’ JEM vol. 203, no. 8, 2006, pages 2021 - 12.09.2012 Bulletin 2012/37 2031, XP008158914 • POWELL ET AL.: ’Large-Scale Depletion of (73) Proprietor: City of Hope CD25+ Regulatory T Cells from Patient Duarte, CA 91010 (US) Leukapheresis Samples.’ J IMMUNOTHER vol. 28, no.
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – May 2017 Foreword Sprinkling the immuno-oncology dust When in November 2015 EP Vantage published its first immuno- oncology analysis we identified 215 studies of anti-PD-1/PD-L1 projects combined with other approaches, and called this an important industry theme. It is a measure of how central combos have become that today, barely 18 months on, that total has been blown out of the water. No fewer than 765 studies involving combinations of PD-1 or PD-L1 assets are now listed on the Clinicaltrials.gov registry. This dazzling array owes much to the transformational nature of the data seen with the first wave of anti-PD-1/PD-L1 MAbs. It also indicates how central combinations will be in extending immuno-oncology beyond just a handful of cancers, and beyond certain patient subgroups. But the combo effort is as much about extending the reach of currently available drugs like Keytruda, Opdivo and Tecentriq as it is about making novel approaches viable by combining them with PD-1/PD-L1. On a standalone basis several of the industry’s novel oncology projects have underwhelmed. As data are generated it will therefore be vital for investors to tease out the effect of combinations beyond that of monotherapy, and it is doubtful whether the sprinkling of magic immuno-oncology dust will come to the rescue of substandard products. This is not stopping many companies, as the hundreds of combination studies identified here show. This report aims to quantify how many trials are ongoing with which assets and in which cancer indications, as well as suggesting reasons why some of the most popular approaches are being pursued.
    [Show full text]
  • Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
    Journal of Clinical Medicine Review Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy Anne M. Macpherson 1, Simon C. Barry 2, Carmela Ricciardelli 1 and Martin K. Oehler 1,3,* 1 Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide 5000, Australia; [email protected] (A.M.M.); [email protected] (C.R.) 2 Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide 5005, Australia; [email protected] 3 Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, Australia * Correspondence: [email protected]; Tel.: +61-8-8332-6622 Received: 29 July 2020; Accepted: 3 September 2020; Published: 14 September 2020 Abstract: Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research Working Group (PDAC Progress Working Group)
    National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research Working Group (PDAC Progress Working Group) Working Group Report March 6, 2019 The report was accepted at the March 6, 2019 CTAC Meeting ______________________________________________________________________________________________________ PDAC Progress WG Report: Accepted by the Clinical Trials and Translational Research Advisory Committee on March 6, 2019 Page 1 TABLE OF CONTENTS Page National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research 3 Working Group (PDAC Progress Working Group) Report Appendix 1: Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research 16 Working Group (PDAC Progress WG) 2018 Roster Appendix 2: Funded Project Summary FY 2015 – FY 2017 • NIH PDAC Funded Projects, Initiative 1: Understanding the 18 Biological Relationship Between PDAC and Diabetes Mellitus • NIH PDAC Funded Projects, Initiative 2: Evaluating Longitudinal Screening Protocols, for Biomarkers for Earl Detection of PDAC 20 and its Precursors • NIH PDAC Funded Projects, Initiative 3: Study New Therapeutic 28 Strategies in Immunotherapy • NIH PDAC Funded Projects, Initiative 4: Developing New Treatment Approaches that Interfere with RAS Oncogene- 33 Dependent Signaling Pathways • NIH PDAC Funded Projects, No Related to the Framework t 38 Initiatives Appendix 3: PDAC Publications Supported by Grants
    [Show full text]